Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Hagiwara, Keitaro ^a,b   Kosaka, Nobuyoshi ^a   Yoshioka, Yusuke ^a   Takahashi, Ryou U ^a   Takeshita, Fumitaka ^a   Ochiya, Takahiro ^a,b  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGONAUTE PROTEIN; EIF2C2 PROTEIN, HUMAN; MICRORNA; STILBENE DERIVATIVE;

ANIMAL; ARTICLE; FEMALE; GENETICS; HUMAN; MOUSE; MOUSE MUTANT; PHYSIOLOGY; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE;

ANIMALS; ARGONAUTE PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; MICE, SCID; MICRORNAS; RNA INTERFERENCE; STILBENES;

EID: 84859768278     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00314     Document Type: Article

References (39)

1. Hartwell, J. L. & Schrecker, A. W. Components of Podophyllin. V. The Constitution of Podophyllotoxin1. J Am Chem Soc 73, 2909-2916 (1951).
2. Baur, J. A. & Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5, 493-506 (2006). (Pubitemid 44136961)
3. Renaud, S. & de Lorgeril, M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339, 1523-1526 (1992).
4. Jang, M. et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220 (1997). (Pubitemid 127696281)
5. Fremont, L. Biological effects of resveratrol. Life Sci 66, 663-673 (2000).
6. Hammell, C. M., Lubin, I., Boag, P. R., Blackwell, T. K. & Ambros, V. nhl-2 Modulates microRNA activity in Caenorhabditis elegans. Cell 136, 926-938 (2009).
7. Stefani, G. & Slack, F. J. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 9, 219-230 (2008). (Pubitemid 351301826)
8. Kong, D. et al. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 27, 1712-1721 (2009).
9. Zhao, J. J. et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283, 31079-31086 (2008).
10. Takeshita, F. et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18, 181-187 (2010).
11. Melkamu, T., Zhang, X., Tan, J., Zeng, Y. & Kassie, F. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 31, 252-258 (2010).
12. Tsang, W. P. & Kwok, T. T. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem 21, 140-146 (2010).
13. Li, Y. et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69, 6704-6712 (2009).
14. Sun, M. et al. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 7, 464-473 (2008). (Pubitemid 351482129)
15. Lee, H. P. et al. Dietary effects on breast-cancer risk in Singapore. Lancet 337, 1197-1200 (1991).
16. Croce, C. M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10, 704-714 (2009).
17. Gaur, A. et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67, 2456-2468 (2007). (Pubitemid 46548930)
18. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100, 3983-3988 (2003). (Pubitemid 36418143)
19. Al-Hajj, M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol 19, 61-64 (2007). (Pubitemid 44885602)
20. Al-Hajj, M., Becker, M. W., Wicha, M., Weissman, I. & Clarke, M. F. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14, 43-47 (2004). (Pubitemid 38167476)
21. Iorio, M. V. et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65, 7065-7070 (2005). (Pubitemid 41161233)
22. Burk, U. et al. Areciprocal repression between ZEB1 and members of themiR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9, 582-589 (2008). (Pubitemid 351772923)
23. Carmell, M. A. & Hannon, G. J. RNase III enzymes and the initiation of gene silencing. Nat Struct Mol Biol 11, 214-218 (2004). (Pubitemid 38282765)
24. Kim, V. N. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6, 376-385 (2005). (Pubitemid 40637855)
25. Lingel, A., Simon, B., Izaurralde, E. & Sattler, M. Structure and nucleic-acid binding of the Drosophila Argonaute 2 PAZ domain. Nature 426, 465-469 (2003). (Pubitemid 37490135)
26. Korpal, M., Lee, E. S., Hu, G. & Kang, Y. The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of Ecadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283, 14910-14914 (2008).
27. Xu, B. et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 350, 207-213 (2011).
28. Burk, U. et al. Areciprocal repression between ZEB1 and members of themiR-200 family promotes EMT and invasion in cancer cells. Embo Reports 9, 582-589 (2008). (Pubitemid 351772923)
29. Rimando, A. M. et al. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J Agric Food Chem 50, 3453-3457 (2002). (Pubitemid 34580577)
30. Stivala, L. A. et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 276, 22586-22594 (2001).
31. Shimono, Y. et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138, 592-603 (2009).
32. O'Carroll, D. et al. A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway. Genes Dev 21, 1999-2004 (2007). (Pubitemid 47267286)
33. Kapetanovic, I. M., Muzzio, M., Huang, Z., Thompson, T. N. & McCormick, D. L. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol (2010).
34. Chiou, Y. S. et al. Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway. J Agric Food Chem 59, 2725-2733 (2011).
35. Chang, T. C. et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26, 745-752 (2007).
36. Dhar, S., Hicks, C. & Levenson, A. S. Resveratrol and prostate cancer: Promising role for microRNAs. Mol Nutr Food Res 55, 1219-1229 (2011).
37. Meister, G. et al. Human Argonaute2 mediates RNAcleavage targeted by miRNAs and siRNAs. Mol Cell 15, 185-197 (2004). (Pubitemid 38950966)
38. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105, 10513-10518 (2008).
39. Suzuki, H. I. et al. Modulation of microRNA processing by p53. Nature 460, 529-533 (2009).